Jacqueline Szmuszkovicz, MD (“Dr. Jackie”) is an Associate Professor of Pediatrics at the University of Southern California (USC). She is the Medical Director of the Kawasaki Disease and Pulmonary Hypertension Programs within the Heart Institute at Children’s Hospital Los Angeles (CHLA).
She graduated cum laude with a B.A. in Chemistry from Kalamazoo College and was elected to Phi Beta Kappa in 1987. She attended medical school at the University of Cincinnati College of Medicine, and completed her Pediatrics residency at Children’s Memorial Hospital/Northwestern University. She completed her fellowship in Pediatric Cardiology at the University of Michigan (C.S. Mott Children’s Hospital).
Dr. Szmuszkovicz began her career at CHLA in 1997, and was the Medical Director of the Heart Transplant Program for 16 years. Her current leadership roles within the CHLA Heart Institute are as the Medical Director of both the Kawasaki Disease Program and the Pulmonary Hypertension Program. The expert CHLA multidisciplinary Kawasaki Disease and Pulmonary Hypertension teams are distinguished for their clinical excellence as well as their teaching and research endeavors.
MIS-C (Multisystem Inflammatory Syndrome in Children)
University of Cincinnati College of Medicine
Childrens Memorial Hospital, Northwestern University: Pediatric Residency
University of Michigan: Pediatric Cardiology
Pediatric Cardiology: American Board of Pediatrics
American Heart Association
Pulmonary Vascular Research Institute
Pulmonary Hypertension Clinicians and Researchers
International Society for Heart and Lung Transplantation
Western Society of Pediatric Cardiology
Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial.
Manlhiot C, Newburger JW, Low T, Dahdah N, Mackie AS, Raghuveer G, Giglia TM, Dallaire F, Mathew M, Runeckles K, Pahl E, Harahsheh AS, Norozi K, de Ferranti SD, Friedman K, Yetman AT, Kutty S, Mondal T, McCrindle BW; International Kawasaki Disease Registry.Can J Cardiol. 2020 Oct;36(10):1598-1607. doi: 10.1016/j.cjca.2020.01.016. Epub 2020 Jul 1.PMID: 32621885
Medium-Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry.
McCrindle BW, Manlhiot C, Newburger JW, Harahsheh AS, Giglia TM, Dallaire F, Friedman K, Low T, Runeckles K, Mathew M, Mackie AS, Choueiter NF, Jone PN, Kutty S, Yetman AT, Raghuveer G, Pahl E, Norozi K, McHugh KE, Li JS, De Ferranti SD, Dahdah N; International Kawasaki Disease Registry *.J Am Heart Assoc. 2020 Aug 4;9(15):e016440. doi: 10.1161/JAHA.119.016440. Epub 2020 Jul 28.PMID: 32750313
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC; KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.Contemp Clin Trials. 2019 Apr;79:98-103. doi: 10.1016/j.cct.2019.02.008. Epub 2019 Mar 3.PMID: 30840903 Clinical Trial.
A Retrospective Review of Infants Receiving Sildenafil.
De A, Shah P, Szmuszkovicz J, Bhombal S, Azen S, Kato RM.J Pediatr Pharmacol Ther. 2018 Mar-Apr;23(2):100-105. doi: 10.5863/1551-6776-23.2.100.PMID: 29720910
Pediatric Perioperative Pulmonary Arterial Hypertension: A Case-Based Primer.
Shah S, Szmuszkovicz JR.Children (Basel). 2017 Oct 24;4(10):92. doi: 10.3390/children4100092.PMID: 29064445 Free PMC article. Review.
MIS-C (Multi Inflammatory Syndrome in Children)
Pediatric Pulmonary Hypertension